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ABSTRACT
Antimicrobial resistance is a key public health concern in Europe. It is known that there are significant
variations in the prevalence of resistance across Europe, and methods to reduce the problem are also assumed
to vary significantly. The ‘Antibiotic Resistance; Prevention and Control (ARPAC)’ Concerted Action project
was funded by the European Commission and conducted by four study groups of the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID). The project established a network of European
hospitals and collated data on antimicrobial resistance prevalence, antimicrobial susceptibility testing
methods, typing methods employed, antimicrobial use, antibiotic policies and practices, and infection control
policies and practices. The ARPAC Consensus Conference, entitled ‘Control of antibiotic resistance in
European hospitals—informing future evidence-based practice’, was held in Amsterdam in November 2004.
The conference was co-hosted by the European Commission, ESCMID and the Dutch Working Party on
Antibiotic Policy (SWAB). Key ARPAC findings were presented and discussed in the context of the
worldwide situation. The conference delivered a set of high-priority recommendations likely to have a
significant impact on antimicrobial resistance. This report summarises these recommendations.
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INTRODUCTION
Antimicrobial resistance is causing major concern
worldwide. There is a fear that a return is being
made to the situation 50 years ago, when there
were few, if any, effective antibiotics, with the
result that numerous infections serious enough to
necessitate hospital admission were usually fatal.
Many of the major resistance problems currently
causing concern emanate from the hospital envi-
ronment. It is difficult at the start of the 21st century
to grasp what life must have been like before
antibiotics were widely available. For example,
staphylococcal septicaemia had a mortality rate of
80% [1], and infective endocarditis and meningitis
had mortality rates approaching 100% [2].
The antibiotic era transformed the treatment
and outcome of infectious diseases, but there is no
doubt that the pendulum has now swung the
other way, and intensive antibiotic use (often
overuse) in hospitals has generated more resist-
ance problems than could ever have been ima-
gined. These problems are compounded by the
ever-increasing immunosuppression that comes
with modern diagnostic and therapeutic modali-
ties, and are magnified further by the opportun-
ities for cross-infection that exist in modern, busy,
often over-crowded, under-staffed hospitals.
It is in this setting that four study groups of the
European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) sought to investi-
gate what measures are being attempted to control
antimicrobial resistance at a pan-European level. It
was already well-known that methicillin-resistant
Staphylococcus aureus (MRSA) is a major scourge of
many European hospitals (http://www.earss.
rivm.nl), but there was less information regarding
the problems with other major antimicrobial-
resistant pathogens. There had been no previous
attempt to quantify these problems in the context
of parallel infection control and antibiotic policy
measures in European hospitals. Furthermore,
there had been no previous efforts to relate the
resistance problem at a hospital level to actual
antibiotic use, which is responsible for the Dar-
winian evolution that selects so many antimicro-
bial-resistant bacteria.
Against this background, the ‘ARPAC’ project
was conceived. This initiative was a Concerted
Action project funded by the European Commis-
sion’s Research Directorate General within the
Fifth Framework Programme (project number
QLK2-CT-2001-00915). The full title of the project
was ‘Development of Strategies for Control and
Prevention of Antibiotic Resistance in European
Hospitals’; the short title was ‘Antibiotic
Resistance; Prevention and Control (ARPAC)’.
Hereafter, the project will be referred to as
ARPAC.
The ARPAC project ran from 1 January 2002 to
30 June 2005, with the work being carried out
under the auspices of four ESCMID study
groups, namely the ESCMID Study Group on
Antibiotic Policies (ESGAP), the ESCMID Study
Group for Antimicrobial Resistance Surveillance
(ESGARS), the ESCMID Study Group on
Nosocomial Infections (ESGNI) and the ESCMID
Study Group on Epidemiological Markers
(ESGEM). The goals of the ARPAC project were
to: (1) lay the foundations for a better under-
standing of the emergence and epidemiology of
antibiotic resistance in human pathogens; and (2)
evaluate and harmonise strategies for the pre-
vention and control of antibiotic-resistant patho-
gens in European hospitals.
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The ARPAC Consensus Conference was the
culmination of this Concerted Action project. The
conference was held in Amsterdam, The Nether-
lands, on 22–24 November 2004, and was
co-hosted by the European Commission, ESCMID
and the Dutch Working Party on Antibiotic Policy
(SWAB). The goals of the Consensus Conference
were:
• to deliver a plenary session giving all delegates
an overview of the key ARPAC findings;
• to allow delegates to explore further the data
gathered in their specific area of expertise and
interest within workshops;
• to allow extensive discussion of the ARPAC
findings in the context of the worldwide status
quo;
• to deliver from each workshop a set of high-
priority strategic goals likely to be broadly
feasible and to have a significant impact on
antibiotic resistance.
Workshop 1 was entitled ‘Surveillance of
antimicrobial resistance’ and aimed to review
current methods of surveillance, the choice of
resistant Alert organisms and resistance preval-
ence. The stated topics covered in the workshop
were:
1. Antibiotic threats among ARPAC Alert organ-
isms.
2. Critical appraisal of antimicrobial surveillance
studies.
3. Towards a consensus for standards for the
surveillance of antimicrobial resistance.
4. Creation of a repository of information about
resistance in Europe.
5. Future of antimicrobial resistance surveillance
in Europe.
Workshop 2 was entitled ‘Antibiotic policies in
European hospitals’ and aimed to address opti-
mal antibiotic stewardship strategies. The stated
topics covered in the workshop were:
1. The role of antibiotic control measures.
2. Antibiotic guidelines and implementation.
3. Education and audit.
4. The role of the laboratory.
5. The role of the pharmacy.
Workshop 3 was entitled ‘Antibiotic prescri-
bing and consumption in European hospitals’
and aimed to explore the prospects for harmo-
nisation of treatment guidelines and how ⁄
why antibiotic consumption should be meas-
ured. The stated topics covered in the workshop
were:
1. Harmonisation of antibiotic prescribing.
2. Measurement of antibiotic consumption.
3. How does consumption relate to resistance?
Workshop 4 was entitled ‘Infection control
policies for containment of antimicrobial resist-
ance, including the role of molecular typing’ and
aimed to address optimal infection control poli-
cies, outbreak investigations and possibilities for
their harmonisation in European hospitals. The
stated topics covered in the workshop were:
1. The organisation of infection control pro-
grammes in healthcare facilities.
2. Infection control guidelines development,
implementation, audit and benchmarking.
3. The role of surveillance of Alert organisms.
4. The role of targeted control of Alert organisms.
5. The role of microbial typing.
6. The current impact of microbial typing.
7. Construction and operation of typing databases
and the ARPAC demonstration databases.
The task of each workshop was to deliver a set
of Consensus Recommendations, which would be
high-priority strategic goals likely to be broadly
feasible and to have a significant impact on
antibiotic resistance. The guidelines and strategies
were constructed in order that they could be
incorporated into local quality improvement
efforts and subjected to intervention trials. The
Consensus Recommendations were categorised as
either ‘high-priority recommendations’, which are
minimum requirements for the control of anti-
biotic resistance, or as ‘desirable recommenda-
tions’, which were perceived to be necessary to
control antibiotic resistance in the long-term, but
which would not be achievable by all hospitals in
Europe in the short-term because of limitations
such as lack of resources.
Each of the workshops also categorised the
recommendations into four groups:
1. Recommendations for individual hospitals in
Europe.
2. Recommendations for national health author-
ities.
3. Recommendations for European health author-
ities.
4. Recommendations for future research.
The detailed scientific results of the ARPAC
project will be published elsewhere. The purpose
of this report is to present the Consensus Recom-
mendations formulated by the participants of the
four ARPAC workshops, which were presented
on the final morning of the Consensus Conference.
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The Recommendations are presented by the four
main target groups as detailed above. Within
these four headings, they are further split by
conference workshop, workshop question, and
finally by ‘high-priority’ vs. ‘desirable’ recom-
mendations.
RECOMMENDATIONS FOR
HOSPITALS
Workshop 1: Surveillance of antimicrobial
resistance
The ARPAC project selected antibiotic-resistant
Alert organisms of clinical and infection control
significance in the hospital environment. These
organisms were MRSA, vancomycin-resistant
enterococci, Klebsiella pneumoniae resistant to
third-generation cephalosporins, Escherichia coli
resistant to quinolones, Acinetobacter baumannii
resistant to carbapenems, and Pseudomonas aeru-
ginosa resistant to carbapenems, quinolones, ami-
noglycosides, ceftazidime or cefepime. Data on
the prevalence of Clostridium difficile were also
collated.
Greater emphasis is being placed upon the
ability of antibiotic susceptibility testing (AST) to
generate resistance surveillance and antibiotic
resistance data across different laboratories, coun-
tries, etc. This necessitates a reassessment of
methods in common use. Data were collated for
2001 from 192 acute-care hospitals (73% of
ARPAC participants) on AST methods, interpret-
ative criteria, participation in quality assurance
programmes, and the detection of specific resist-
ance phenotypes. Of the 192 responding hospitals,
170 used a disk-diffusion method routinely for
AST in 2001; the most commonly reported
method involved the use of disks manufactured
by Oxoid. There were significant variations in the
use of disk-diffusion according to geographical
region. MICs were determined routinely in 135
(70%) hospitals, of which 82% used the Etest
method. In total, 173 (90%) hospitals reported
using breakpoints to interpret AST results; Clin-
ical Laboratory Standards Institute (CLSI; previ-
ously NCCLS) guidelines were used most widely
(84% of hospitals), although other national guide-
lines were also employed. Most hospitals partici-
pated in an external quality assurance
programme and conducted internal quality con-
trol, although the frequency with which controls
were included varied significantly according to
geographical region.
High-priority recommendations
• Local hospitals should draw up a list of local
Alert organisms that are relevant to the local
situation.
• AST methods to detect new and emerging
resistant phenotypes should be standardised;
these methods should be used by other hos-
pitals with which data will be compared.
• Each hospital should formalise its antibiotic
resistance surveillance methods.
• It is essential that hospitals should participate
in quality assurance schemes.
• Agreed Alert organisms should be referred to
national reference laboratories as appropriate.
• Outbreak strains should be investigated for
epidemiological purposes.
• Isolates with an unusual resistance phenotype
should be routinely stored and investigated,
either locally or by an expert in another
laboratory.
Workshop 2: Antibiotic policies in European
hospitals
The ARPAC project found significant associations
between the presence of several antibiotic control
measures and reduced antibiotic use, including the
presence of an antibiotic formulary, a multidis-
ciplinary drugs and therapeutics committee (DTC),
and an active education programme on antibiotic
use and resistance. Whilst the absolute reduction in
antibiotic consumption might be perceived as
small, this is in line with most of the evidence from
the published literature, which confirms that it is
extremely difficult (if not impossible) to achieve,
and certainly to maintain, significant changes in the
volume of prescribing [3]. The effects of inter-
ventions often erode over time, perhaps because of
the high mobility of hospital doctors, and therefore
require continual programme reinforcement in
the case of restrictive measures, and repetition in
the case of educational programmes. Within the
hospitals that participated in the ARPAC project,
perhaps the greatest shortcoming was an almost
complete absence of audit activities. Clearly, this
must change if the quality of prescribing is to be
ascertained and improved. All the published
evidence suggests that there is much scope for
improvement in this area.
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Effectiveness of antibiotic control measures
High-priority recommendations
• All hospitals should have an antibiotic stew-
ardship programme with strategic goals, and a
multidisciplinary DTC with expertise and
authority regarding antimicrobial agents.
• All hospitals should have a written Antibiotic
Formulary, which should be easily accessible
to all prescribers (e.g., paper copy, intranet)
and updated annually where feasible.
Desirable recommendations
• Multidisciplinary antibiotic committees, poli-
cies, restricted lists and computerised prescri-
bing should be introduced where possible,
followed by an assessment of their impact
according to the Cochrane Effective Practice
and Organization of Care Group (EPOC)
guidelines (http://www.epoc.uottawa.ca).
• An Antibiotic Co-ordinator should be appoin-
ted to collect and feed back data, perform
audits of compliance with guidelines, and
inform the Antibiotic Committee regarding
the quality of prescribing.
Successful guidelines
High-priority recommendations
• The DTC should maintain responsibility for
antimicrobial policy management in response
to national guidelines, local requirements and
susceptibility data.
• All clinical practitioners should accept respon-
sibility for following good antimicrobial pre-
scribing and policy practice.
• The DTC should take responsibility for pru-
dent antimicrobial prescribing by developing
and implementing guidelines.
Laboratory recommendations
High-priority recommendations
• Annual antimicrobial susceptibility data
should be analysed (with duplicates
removed) and fed back to inform prescribers,
policies and formularies in different areas of
the hospital.
• Interpretative reporting should be employed
to anticipate difficult-to-detect resistance
mechanisms and treatment failures.
Desirable recommendations
• First-line agents should be listed first in
reports of susceptibility test results.
• Awareness of cost-effectiveness among clini-
cians should be encouraged.
• There should be a limit to the number
of agents reported (a figure of six is sugges-
ted).
Education and audit
High-priority recommendations
• Educational initiatives should be continuous
and involve multimedia.
• Audit should be initiated and developed
where there is poor performance, as revealed
by antimicrobial resistance surveillance and
antimicrobial usage data.
Workshop 3: Antibiotic prescribing and
consumption in European hospitals
One of the major achievements of the ARPAC
project was to enable many hospitals to calcu-
late their antibiotic consumption for the first
time. This not only allows benchmarking with
other hospitals with a similar case-mix, but also
allows a clearer understanding at a local level of
what drives current resistance problems and,
importantly, what might be done to control
them. Whilst there are many technical issues to
be solved concerning the best ways to study
relationships between antibiotic consumption
and resistance, and the best ways to benchmark,
enough is known to allow ARPAC to make
some basic recommendations which, it is be-
lieved, are achievable for most hospitals, partic-
ularly if they have computerised pharmacy
stock orders. Most of this work will no doubt
be carried out in the future by pharmacists, as it
is clear from ARPAC data that there is huge
potential in Europe for an increased role for
pharmacists, not only in measuring and bench-
marking consumption, but also in many other
aspects of antibiotic stewardship, including
being a key member of multidisciplinary DTCs
and teams that visit hospital wards to guide
and audit antibiotic therapy.
Antibiotic consumption
High-priority recommendations
• Whole-hospital, antimicrobial usage data, cat-
egorised by class, should be recorded quar-
terly (yearly, if based on pharmacy purchases)
using the WHO-defined unit of defined daily
dose (DDD) ⁄ 100 patient-days and the Ana-
tomical Therapeutic Chemical (ATC) classifi-
cation system.
942 Clinical Microbiology and Infection, Volume 11 Number 11, November 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 937–954
• Reasons for high ⁄ low levels and changes in
consumption of antimicrobial agents should
be investigated and documented.
• Pharmacy computer databases to store and
retrieve antibiotic usage data should be imple-
mented.
Desirable recommendations
• Participation in multicentre ⁄multinational
benchmarking surveillance networks ⁄ surveys
should be encouraged.
• Antimicrobial usage data should be reviewed
according to individual wards ⁄units, diagno-
sis and the proportion of patients treated with
an antimicrobial agent.
• Datashouldberecordedandreviewedmonthly.
• In addition to DDD ⁄ 100 patient-days, locally
defined prescribed daily doses (PDD) ⁄ 100
patient-days can be reported.
• Antimicrobial usage data should be combined
with drug utilisation prevalence studies at the
patient level (duration of therapy, treatment
failure).
• Antimicrobial usage data should be fed back
to prescribers.
Relationship between consumption and resistance
High-priority recommendations
• Choices of antibiotic–bacteria combinations
should be based on local epidemiology.
Desirable recommendations
• Ongoing surveillance and analysis of antimi-
crobial resistance and consumption should be
carried out, if possible using computerised
prescribing data and at the individual patient
level.
Pharmacy and antibiotic use
High-priority recommendations
• There should be provision of clinical pharmacy
services to support antibiotic prescribing.
• Pharmacists should be part of the multidisci-
plinary DTC.
• Pharmacy departments should be involved in
measuring and analysing antibiotic consump-
tion as part of a multidisciplinary team.
Desirable recommendations
• Antibiotic pharmacists should be appointed
with a hospital-wide brief to:
review antibiotic orders, e.g., selected drugs,
duration of therapy;
design and promote clinical practice guide-
lines;
implement and run antibiotic ‘switch’ pro-
grammes;
document effectiveness of interventions.
Harmonisation of antibiotic prescribing
High-priority recommendations
• Guidelines must be evidence-based, taking
account of local epidemiology.
• Glycopeptides should only be used for pro-
phylaxis in high-risk surgery if there are
clinical problems with MRSA infections.
• Key antibiotics should be reserved, e.g., carb-
apenems, glycopeptides, fourth-generation
cephalosporins, oxazolidinones.
Desirable recommendations
• Participation in networks to share and increase
expertise on antibiotic management pro-
grammes should be encouraged.
• Antibiotics used for prophylaxis should not be
used for therapy.
Workshop 4: Infection control policies for
containment of antimicrobial resistance,
including the role of molecular typing
The ARPAC project identified major gaps in staff
resources available to European hospitals for their
infection control programmes, with significant
regional differences. For instance, a majority of
ARPAC hospitals did not meet recommendations
based on the SENIC study [4] that an infection
control programme should be operated with at
least one infection control nurse per 250 acute-
care beds and one infection control physician per
1000 beds. The ARPAC project also revealed that,
while most hospitals had an ongoing programme
to promote the use of standard infection control
precautions, only about half conducted regular
audit of healthcare compliance with these pre-
cautions. In addition, only two-thirds of the
hospitals surveyed recommended the use of
alcohol-based solutions for hand hygiene,
although this method has been shown in the
literature to be most efficacious for hand decon-
tamination. Moreover, the ARPAC project found
a significant association between the use of
alcohol-based hand disinfection and lower rates
of MRSA infection. Other significant predictors of
lower resistance rates were a policy for placing
MRSA-colonised patients in single rooms, and
having no practical problem in implementing
such a policy. The ARPAC project found that most
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hospitals have developed a laboratory system for
notification of patients colonised by selected Alert
antibiotic-resistant organisms to the infection
control team, most frequently, but not exclusively,
targeted at MRSA. It was apparent, however, that
most of these hospitals did not fully implement
contact isolation and barrier precautions (single
room placement and protection with gloves and
gown for patient care procedures) for patients
colonised by Alert organisms, nor did they
perform active surveillance cultures for early
detection of patient colonisation with MRSA.
At the laboratory level, rapid molecular typing
techniques are becoming essential tools for mon-
itoring the geographical spread of particular
virulent, epidemic or antibiotic-resistant patho-
gens. Microbial typing can be performed for
different reasons and at different levels, including
the local hospital level, the regional level and the
(supra)national level. Probably the most frequent
reason at the local level is to rapidly identify cases
of cross-infection caused by antibiotic-resistant
strains. Thus, within a hospital, typing allows
recognition and confirmation of outbreaks of
infection caused by particular antibiotic-resistant
bacteria (i.e., cross-infection between patients),
leading to action by infection control teams. Many
different methods are available for typing micro-
organisms, and the ARPAC project gathered data
on the typing methods being used by participa-
ting hospital laboratories around Europe for
typing Alert organisms. It became apparent that
a wide range of typing methods was currently in
use, but that there was very little uniformity or
standardisation of the methods being used. In the
past decade, several networks, including ARPAC,
have attempted to standardise methodology and
establish typing databases to monitor the spread
of important pathogens. These pilot databases
have demonstrated the feasibility of the database
approach at a European level, but much more
work, reflected in the following recommenda-
tions, is required to make the database approach a
reality.
General infection control policies
High-priority recommendations
• Hospital management should ensure that its
infection control programme is implemented
by a sufficient staff resource, meeting at least
the levels recommended by the SENIC study
(one infection control physician per hospital,
and one infection control nurse per 250 acute-
care beds).
• Hospital infection control programmes should
ensure implementation of standard precau-
tions, including the use of alcohol-based solu-
tions for hand hygiene, as well as audit of the
compliance of healthcare workers with these
precautions.
• Hospitalmanagement should provide sufficient
isolation facilities (single patient rooms) and
staff reinforcement to cope with the workload
incurred by placing patients in contact isolation.
• Control of healthcare-associated infection
(HAI) should be part of the curriculum of
medical and nursing undergraduate students.
Desirable recommendations
• Infection control personnel should use feed-
back of HAI and antimicrobial resistance
surveillance data, together with the results of
compliance studies, in educational sessions for
healthcare workers.
• Control of HAI should be part of all induction
training programmes for newly appointed
healthcare workers, including medical doctors.
• Hospital infection control teams should consi-
der implementing a link nurse system, link
medical doctors, or link high-risk unit teams.
• There should be better retrieval of demogra-
phic data for surveillance of HAIs.
Surveillance and control policies for antibiotic-
resistant Alert organisms
High-priority recommendations
• Hospitals should have a system to identify
patients at high risk for carriage of Alert
organisms.
• Rapid microbiological methods should be
validated and implemented for screening and
detection of Alert organism carriers among
high-risk patients admitted to acute-care hos-
pitals, particularly in intensive care units.
• Local surveillance, outbreak detection and
ad-hoc control measures should be developed
and evaluated for containment of emerging or
importable Alert organisms.
Desirable recommendations
• The transmission capacity and attributable
morbidity, cost and mortality of infection with
specific Alert organisms should be estimated
within the local and regional patient popula-
tions.
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• Compliance of healthcare workers with inter-
nal guidelines for Alert organism surveillance
and control measures should be audited regu-
larly, with performance scores being fed back
to healthcare workers.
Containment of MRSA
High-priority recommendations
• Every institution should establish an MRSA
surveillance, alert and control programme that
is adjusted to local and regional circumstances.
The surveillance system should include the
automated flagging of colonised patients upon
readmission.
• Active MRSA surveillance cultures should be
performed so that the MRSA reservoir among
high-risk patients can be ascertained faster
and more exhaustively.
• Screening of healthcare workers for MRSA
carriage is indicated if associated with an
MRSA outbreak, at least in settings where
the incidence has not reached an endemic
level.
• MRSA-colonised patients should be placed
in single rooms or in an isolation ward;
healthcare workers should wear gowns
and gloves, at least before taking care of
patients.
• Attempts should be made to decolonise
patients who are MRSA carriers, in the
absence of colonised chronic lesions or col-
onised indwelling devices such as endotra-
cheal tubes.
Desirable recommendations
• Mortality and morbidity associated with
MRSA infections should be monitored.
Establishment of electronic typing databases for key
Alert organisms
High-priority recommendations
• Hospitals should have a policy to prospec-
tively collect Alert organisms for typing.
• Direct access to rapid molecular typing facil-
ities, preferably locally based, should be pro-
vided.
Desirable recommendations
• Individual hospitals should have electronic
access to centralised typing databases for key
Alert organisms.
• Hospital information technology systems
should enable typing information to be record-
ed in patients’ records.
• Individual hospitals should have access to
robust typing methods to establish a local
database.
RECOMMENDATIONS FOR
NATIONAL HEALTH AUTHORITIES
Workshop 1: Surveillance of antimicrobial
resistance
National bodies should be responsible for monit-
oring emerging resistance problems, which,
although not widespread in local situations, may
pose future threats. National surveillance of Alert
organisms should be altered accordingly. It is at
national level that decisions should be taken
regarding laboratory methodology to ensure that
local laboratories are producing comparable and
standardised data. Inevitably, standardisation of
methods and surveillance systems will not come
without financial costs and a requirement for
expert knowledge and advice—all of which
should be provided at national level and made
available to individual hospitals.
High-priority recommendations
• A list of nationally agreed and relevant Alert
organisms should be defined.
• Alert organisms should be typed using
molecular techniques.
• A network of reference laboratories should be
established and consolidated.
• National bodies should facilitate standardisa-
tion of all methodologies in local laboratories.
• National bodies should establish and consol-
idate quality assurance programmes for use in
local laboratories.
• National sampling programmes should be
coordinated nationally.
• National surveillance and control of commu-
nicable disease programmes should be estab-
lished, sustained and networked across
countries to allow comparability.
Workshop 2: Antibiotic policies in European
hospitals
This is clearly an area that would benefit from a
degree of national coordination and input of
resource. While guidelines should always be
tailored to local situations, particularly in the
context of local resistance issues, the resource for
the assembly of the evidence base is not within
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the capabilities of individual hospitals, and
the same may be true for expert opinion in the
absence of a robust evidence base. Whilst the
ARPAC project did not uncover evidence on
which to base guidelines influencing antibiotic
consumption or resistance, they are clearly widely
implemented. Formularies and educational pro-
grammes will be moulded by input at a national
level. It is also likely that a national steer on
educational issues is likely to be beneficial, at the
level of both undergraduates and prescribers.
Finally, a requirement for audit and demonstra-
tion of quality antibiotic prescribing (clearly not
performed adequately at the moment) could
become a hospital accreditation issue.
Effectiveness of antibiotic control measures
High-priority recommendations
• There should be national programmes to
coordinate antibiotic stewardship, policy and
practice. These should be integrated with
programmes for monitoring antibiotic resist-
ance and consumption.
Desirable recommendations
• National programmes should coordinate
multicentre evaluations of control measures
according to EPOC guidelines.
Successful guidelines
High-priority recommendations
• Strict methodology in accordance with ‘The
Consensus Council Inc.’ (http://www.
agree.org) should be used.
Desirable recommendations
• Interactions between national surveillance of
antimicrobial consumption and resistance data
should be reviewed annually.
• Local policies should be encouraged, e.g.,
performance indicators.
Laboratory recommendations
High-priority recommendations
• There should be a national accreditation sys-
tem for laboratories.
Education and audit
High-priority recommendations
• National guidelines should be endorsed.
• Major national educational programmes should
be coordinated.
• Audits on antibiotic prescribing should be pro-
moted,particularlycompliancewithguidelines.
Workshop 3: Antibiotic prescribing and
consumption in European hospitals
A national approach to benchmarking of hospital
antibiotic consumption is likely to be helpful in
gaining the extra resources necessary. Similarly,
a national programme of education of pharma-
cists to create more clinical specialists with a
particular expertise in antibiotic prescribing is
essential. Such a programme has recently been
initiated at the Hammersmith Hospital in Lon-
don; although a distance-learning package is
planned, it is essential that other countries also
take similar initiatives.
Whilst harmonisation of prescribing of partic-
ular antimicrobial agents may not be desirable on
a wide scale, there are issues, such as non-
availability of individual agents, that can best be
addressed at a national level, and this is certainly
the case when assessing the need to restrict key
antibiotics for fear of undue toxicity or resistance.
National programmes to coordinate surveil-
lance of resistance and consumption, such as
those already operating in The Netherlands and
certain Scandinavian countries, are felt to be very
valuable and should be expanded. Computerised
antibiotic prescribing and analysis of emergence
of resistance in individual patients are desirable,
but remain a long-term goal for most hospitals. A
national steer in this area would be helpful.
Antibiotic consumption
High-priority recommendations
• Resources to retrieve, collate and analyse
antibiotic usage data, including computer
support, software and personnel, should be
provided.
• The WHO-recommended unit of DDD ⁄ 100
patient-days should be endorsed as a standard
unit of measurement for antibiotic consump-
tion.
Desirable recommendations
• Participation in international collaboration and
benchmarking should be the norm.
• National surveillance systems for collation,
feedback and benchmarking of data should be
established.
Pharmacy and antibiotic use
High-priority recommendations
• National antibiotic guidelines for clinical phar-
macy services should be provided.
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Desirable recommendations
• Nationwide education ⁄ training ⁄ accreditation
for antibiotic pharmacists should be pro-
moted.
Harmonisation of antibiotic prescribing
High-priority recommendations
• Inappropriate use of restricted agents should
be monitored and action taken.
Workshop 4: Containment of antimicrobial
resistance: role of infection control policies and
molecular typing
The ARPAC Project revealed major gaps in the
human resources available to European hospi-
tals to conduct effective infection control pro-
grammes, in terms of both insufficient numbers
of staff and a lack of nurses and physicians
specially trained for these positions. This deficit
showed marked regional variations, being more
pronounced in less affluent countries. It is
essential that national authorities review these
situations urgently and redress deficits accord-
ing to minimum standards. Likewise, a majority
of hospitals, particularly in less affluent coun-
tries, reported frequent practical problems with
isolation policies because of a lack of nursing
staff or insufficient room capacity. Again,
national health authorities should act urgently
to remove these serious obstacles to effective
isolation, which may otherwise allow for uncon-
trolled spread of epidemic resistant Alert organ-
isms, leading to adverse patient outcomes and
enormous additional costs for the healthcare
system. Political leadership is key in making
prevention and control of HAI and antimicro-
bial resistance a national health priority, with
objectivity in the accreditation and quality
assurance programme for healthcare facilities.
Surveillance-derived quality indicators may be
useful if designed and analysed carefully to
stimulate and monitor progress of prevention
programmes at an institutional level.
At the national level, typing allows recognition
of the epidemic spread between hospitals of
particular antibiotic-resistant bacteria, possibly
requiring action by national health authorities.
ARPAC identified a need for national health
authorities to establish a network of typing
expertise and availability, and to coordinate the
common use of standardised operating proce-
dures to enable data to be shared among labor-
atories. Although typing is clearly of benefit in
recognising outbreaks of cross-infection at the
local hospital level, little is known about the
overall impact of typing on controlling the spread
of hospital-acquired infection in different types
and sizes of hospitals. Such a programme should
be coordinated and funded adequately at the
national level, with national reference facilities
being established for key antibiotic-resistant Alert
organisms.
General infection control policies
High-priority recommendations
• National authorities should provide support
and require acute-care hospitals to implement
infection control staff levels that meet at least
those recommended by the SENIC study (one
infection control physician per hospital and
one infection control nurse per 250 acute-care
beds) [4].
• Infection control staff (physicians and nurses)
should receive specialised training and certi-
fication of competence according to national
standards.
• Provision of sufficient isolation room capacity
in acute-care hospitals should be ensured.
• National infection control standards for the
complete healthcare system should be devel-
oped and implemented; these should be con-
sidered standards of care.
• Development of educational material, e.g., for
hand hygiene (alcohol-based hand rubs),
should be supported and adapted for different
professional groups.
Desirable recommendations
• A national nosocomial infection surveillance
system that meets European criteria and case
definitions should be developed and ⁄ or sus-
tained.
Surveillance and control policies for antibiotic-
resistant Alert organisms
High-priority recommendations
• Standardised Alert organism definitions,
detection and reporting methods should be
developed for use by infection control teams
for local surveillance, and may also be
applied to multicentre surveillance networks.
Appropriate data protection guidelines
should be enforced to prevent misuse of
data.
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• A national surveillance system should be
established to monitor the institutional inci-
dence of MRSA acquisition ⁄ infection and
allow hospital benchmarking of MRSA rates.
• Financial and regulatory support should be
provided to allow local deployment of ade-
quate human and technical resources for
effective Alert organism surveillance and con-
trol efforts (nursing staff, laboratory facilities,
isolation room capacity).
• A national surveillance programme for Alert
organisms in acute-care hospitals should be
established and linked to an early outbreak
detection and response system.
Desirable recommendations
• Regional care networks should be established
to help hospitals and long-term care facilities
conduct harmonised surveillance and man-
agement of MRSA and other epidemic Alert
organisms.
• National guidelines and standards for control
of MRSA (and other relevant Alert organisms)
in healthcare facilities should be developed,
updated and implemented.
• Prevention of community-based transmission
of MRSA should be tested and implemented
through regional infection control networks.
Establishment of electronic typing databases for key
Alert organisms
High-priority recommendations
• National health authorities should establish
an inventory of typing expertise and avail-
ability.
• Molecular typing methods should be stand-
ardised at the national level and standard
operating procedures should be made avail-
able to local laboratories.
• A national network of laboratories capable of
undertaking molecular typing at the local level
should be established.
• There should be support and provision for
training of laboratory staff in typing methods
and the use of typing databases.
• External quality control ⁄proficiency pro-
grammes should be established with panels
of well-characterised strains.
• Funding should be provided for the necessary
staff and equipment ⁄ consumables at the local
level.
• National reference laboratory facilities should
be established for key Alert organisms.
RECOMMENDATIONS FOR
EUROPEAN HEALTH AUTHORITIES
Workshop 1: Surveillance of antimicrobial
resistance
The ARPAC study identified a wide variation in
AST methods among European hospitals. Of key
significance, there was considerable variation in
the breakpoints used to interpret AST results. The
lack of harmonised breakpoints among methods
in different countries, or even within the same
country, often prevents meaningful comparison
of resistance rates and monitoring of the devel-
opment of resistance in international surveillance
systems. The European Committee for Antimi-
crobial Susceptibility Testing (EUCAST) is a
standing ESCMID committee, set up to standard-
ise susceptibility testing in Europe so that com-
parable results and interpretations are produced.
EUCAST has published documents proposing
standardised methodologies and breakpoints
[5–7].
High-priority recommendations
• There should be a European-wide body to
coordinate and ensure the sustainability of
surveillance efforts, including external quality
assurance.
• Harmonisation of approaches across Europe
should be encouraged.
• A list of Alert organisms (e.g., MRSA, vanco-
mycin-resistant S. aureus, vancomycin-resist-
ant enterococci, penicillin-resistant group A
streptococci) should be established at a Euro-
pean level.
• The activities of EUCAST should be encour-
aged and extended.
Workshop 2: Antibiotic policies in European
hospitals
One of the most intriguing ARPAC findings was
the highly significant geographical variation in
antibiotic formularies, coupled with the associ-
ation between the existence of a formulary and
lower antibiotic consumption. Whilst ARPAC
project data cannot be used to attribute cause
and effect, a consensus is widely held that there
are regional and cultural issues regarding restrict-
ive control measures that may best be addressed
with Europe-wide input. Similarly, although per-
haps in the longer term, hospitals may benefit
from adherence to European guidelines or initi-
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atives on other aspects of antibiotic stewardship,
including education, audit and hospital accredi-
tation programmes in antibiotic prescribing. A
European centre for implementation of evidence-
based guidelines would clearly be a major step
forwards, as would a European core educational
curriculum.
Effectiveness of antibiotic control measures
High-priority recommendations
• There should be a Europe-wide organisation
to coordinate multicentre evaluations of
control measures, and to oversee harmonisa-
tion of antibiotic stewardship, policy and
practice.
• Such an organisation should coordinate its
activities with national counterparts and
Europe-wide bodies monitoring antibiotic
resistance and consumption.
• Europe-wide minimum standards of antibiotic
stewardship for hospitals should be estab-
lished.
Successful guidelines
High-priority recommendations
• ‘The Consensus Council Inc.’ process for deri-
ving the evidence base for guideline develop-
ment should be utilised (http://
www.agree.org).
• Performance indicators should be agreed.
Laboratory recommendations
High-priority recommendations
• There should be a national accreditation sys-
tem for laboratories.
Education and audit
High-priority recommendations
• Educational programmes on antibiotic prescri-
bing should be developed and exchanged.
• Multinational explorative and educational site
visits to encourage mutual learning and reflec-
tion regarding antibiotic usage should be
organised.
• A European standard for auditing should be
formulated.
Workshop 3: Antibiotic prescribing and
consumption in European hospitals
Within the hospitals that participated in the
ARPAC project, there were issues regarding
benchmarking antibiotic consumption, marked
differences in hospital antibiotic usage data with-
in individual countries, and a widespread lack of
clinical pharmacy input into antibiotic prescri-
bing, all of which would benefit from a European
initiative, including programmes for implemen-
tation and education. Similarly, the lack of
consistency in availability of certain antibiotic
classes causes problems at an individual hospital
policy level. It may be possible to solve these
problems at a European level. As recommended
by Workshop 2, perhaps hospital or pharmacy
accreditation at a European level is a goal worth
working towards.
Antibiotic consumption
High-priority recommendations
• The WHO-recommended standard measure-
ment of DDD ⁄ 100 patient-days should be
endorsed.
• A surveillance system for Europe-wide feed-
back and benchmarking of hospital antibiotic
consumption should be implemented.
• Computerised tools for measuring antibiotic
consumption (e.g., transfer of data, data ⁄ con-
trol checks, analysis, feedback) should be
developed.
• Collaboration with multinational surveillance
systems should be promoted.
Harmonisation of antibiotic prescribing
High-priority recommendations
• Proposals for a framework of common princi-
ples and quality standards for hospital diag-
nosis and treatment of infections should be
developed.
• Use of evidence-based guidelines should be
encouraged.
• Development of diagnostic tools for infections
in hospitals should be encouraged.
Desirable recommendations
• Networks of hospital antibiotic management
programmes should be implemented.
• Licensing of and registered indications for new
antibiotics should reflect true clinical needs.
Workshop 4: Containment of antimicrobial
resistance: role of infection control policies and
molecular typing
Pooling of expertise at the European level would
benefit the much-needed development of profes-
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sional training of HAI control specialists at the
national level. In addition, assessment of the
public health impact of infections caused by
resistant bacterial pathogens in healthcare settings
at the European level would better define the
costs ⁄benefits of control programmes and the
merits of different models of healthcare delivery,
notably in the context of increasing patient mobil-
ity within the EU.
Similarly, pooling of typing expertise and an
exchange of laboratory data at the European level
should help to identify particular virulent and ⁄ or
epidemic clones spreading in Europe, and will aid
in the development of newer and better typing
methods that exploit new proteomic and genomic
approaches. A key component of such activity
would be the establishment and use of validated
typing databases by large European collaborative
networks of laboratories. For this to occur, Euro-
pean health authorities should promote and fund
the harmonisation of typing methods for key
Alert organisms at the European level, including
the provision of advanced training to facilitate the
dissemination of methodology and best standards
of laboratory practice.
General infection control policies
High-priority recommendations
• Concepts for a European core curriculum
training programme for infection control nur-
ses and physicians should be developed and
approved by professional groups.
Surveillance and control policies for antibiotic-
resistant Alert organisms
High-priority recommendations
• The public health impact of infections caused
by antimicrobial-resistant bacterial pathogens
should be determined. Findings on the human
and financial costs should then be used to
inform patient organisations, policy-makers
and the media, and should be considered in
perspective with other disease burdens.
• National surveillance of community-acquired
and hospital-acquired MRSA infections
should be harmonised, using Europe-wide
standard definitions and denominators.
• The European Council should encourage
national authorities to reduce the incidence
of MRSA infections throughout Europe.
• International surveillance of MRSA infections
should be strengthened.
• Cross-border patient transfer procedures
should be harmonised, and regional cross-
border care networks should be strengthened,
to ensure proper exchange of health infor-
mation and to limit international dissemin-
ation of Alert organisms of epidemiological
significance, such as MRSA.
Establishment of electronic typing databases for key
Alert organisms
High-priority recommendations
• Typing methods for key Alert organisms
should be harmonised at the European level.
• Advanced training should be provided to
disseminate best standards of laboratory
practice.
• Data exchange methods (and their availability)
should be coordinated for important clones of
Alert organisms.
• New practical arrangements should be agreed
to enable easier and more cost-effective inter-
national exchange of important strains of
bacteria.
Desirable recommendations
• The establishment of typing databases at the
European level should be supported and
coordinated.
FUTURE RESEARCH
Workshop 1: Surveillance of antimicrobial
resistance
The surveillance of antimicrobial resistance alone
is likely to have a minimal effect on changing
practices to try to reduce the problem of resist-
ance in Europe. Robust surveillance data are
crucial, however, when assessing the impact of a
range of possible interventions to tackle the
problem. Antimicrobial resistance rates are an
obvious outcome measure to assess the effect of
interventions, such as the role of antibiotic poli-
cies, antibiotic prescribing and infection control
measures on reducing resistance.
High-priority recommendations
• There should be a European programme to
establish how practices in clinical microbio-
logy can be informed by epidemiology.
• The role of different denominators should be
investigated.
• Any research carried out should be both
qualitative and quantitative.
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• The current situation regarding the prevalence
of all Alert organisms across Europe should be
established via representative surveys.
• European research should focus on resistance
determinants and selection pressures, from
bacterial populations down to genes.
• Research should also focus on the impact of
antibiotic usage on normal flora, the environ-
ment and the community.
• There should be a focus on interventions to
control the spread of resistance genes and
resistant organisms.
Workshop 2: Antibiotic policies in European
hospitals
Whilst some of the ARPAC findings corroborate
previous findings, the published literature is of
poor quality and much more research needs to be
performed. In particular, there is a lack of good-
quality studies showing an improved clinical
outcome (or at least no harm to patients) or reduced
resistance following interventions to decrease or
improve the quality of antibiotic use. While mod-
ern techniques, such as time-series analysis, should
make it possible for individual hospitals to gener-
ate their own good-quality data, there is also a need
for pan-European multicentre randomised control
studies to negate confounding issues and show the
appropriateness of such interventions. There is a
huge need for such activities at all levels, ranging
from guideline implementation to education and
audit, and the role of multidisciplinary teams, etc.
Effectiveness of antibiotic control measures
High-priority recommendations
• There should be a European programme to
evaluate interventions for improving the qual-
ity of antibiotic use in European hospitals,
reducing consumption and resistance, and
improving patient outcomes.
Desirable recommendations
• There should be a European programme for
development and evaluation of new antibiotics.
Successful guidelines
High-priority recommendations
• Research into compliance with guidelines
should be undertaken, including behavioural
aspects.
• There is a need to further mine ⁄model the
large ARPAC database.
Laboratory recommendations
High-priority recommendations
• The influence of laboratory results on patient
outcomes, including cost-effectiveness and
rapid methods, should be evaluated.
• The most relevant tests for advising on com-
bination treatments should be assessed.
Education and audit
High-priority recommendations
• Independently funded studies should be per-
formed to provide the evidence for efficacy of
‘older’ antibiotics.
• Successful methods for audit and education
should be established.
Workshop 3: Antibiotic prescribing and
consumption in European hospitals
Many ‘older’ antibiotics are used increasingly for
the treatment of multiresistant infections because
of a lack of new alternatives. Usually there is no
proper evidence base, other than clinical experi-
ence, as these agents were developed and marke-
ted before the advent of modern clinical trials.
One such example is the use of agents such as the
tetracyclines and co-trimoxazole for the treatment
of MRSA infections. A European facility for
scientific assessment of the efficacy of such treat-
ment would be a major beneficial development.
The assessment of combination therapies requires
similar facilities.
Antibiotic consumption
High-priority recommendations
• A standard definition for patient-days, e.g.,
occupied bed-days, should be developed and
tested.
• The best ways to benchmark antibiotic
consumption and the effects of feedback
(quantitative, qualitative) should be investi-
gated.
• The consequences for patient outcomes of
reducing hospital antibiotic usage should be
investigated.
Relationship between consumption and resistance
High-priority recommendations
• The effects of changes in consumption on
resistance rates (e.g., reversibility of resistance,
including the influence of reduction of the use
of key antibiotics on MRSA) should be studied.
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Desirable recommendations
• The best ways to explore the relationship
between antibiotic consumption and resistance
should be established, e.g., DDD ⁄ 100 patient-
days, number of patients treated or duration of
treatment.
Pharmacy and antibiotic use
High-priority recommendations
• The effect of antibiotic pharmacists on improv-
ing and reducing antibiotic prescribing should
be investigated.
Desirable recommendations
• The most efficient pharmacy-based interven-
tions should be established.
Harmonisation of antibiotic prescribing
High-priority recommendations
• Evidence-based stratification of patients for
empirical therapy should be performed.
• The feasibility of harmonising existing
national, evidence-based guidelines, e.g., on
infective endocarditis, neurosurgical infections
and surgical prophylaxis, to create Europe-
wide policies should be studied.
• The potential dangers of harmonisation, with
regard to the efficacy and selection of resist-
ance, should be established.
Desirable recommendations
• The optimal use of combination therapies for
the treatment of multiresistant microorgan-
isms should be established.
Workshop 4: Containment of antimicrobial
resistance: role of infection control policies and
molecular typing
Some of the ARPAC findings corroborate previ-
ously published evidence that use of alcohol-
based hand disinfection and full implementation
of isolation policies for colonised patients can be
effective in limiting the spread of resistant bac-
terial pathogens of global concern, such as MRSA.
There is, however, a glaring lack of robust
evidence from well-designed epidemiological
studies to ascertain the burden of disease and
the direct costs associated with infections caused
by these pathogens in European hospitals, and to
determine the effectiveness and cost-effectiveness
of currently recommended or innovative control
interventions.
In addition to its role in the immediate control
of cross-infection, typing can also be performed to
investigate diversity in the microbial population
at the European level and to study the relation-
ships between epidemiological markers, antibiotic
resistance, epidemicity and pathogenicity mecha-
nisms. Such studies would be particularly well-
served by the establishment and use of validated
typing databases by large European collaborative
networks of laboratories, but further research on
intra- and inter-laboratory reproducibility and
standardisation of typing methods, including
strategies for data analysis, is urgently needed.
General infection control policies
High-priority recommendations
• The burden of HAI and the effectiveness of
infection control outside the acute-care setting
should be assessed.
• Optimal staff levels for effective infection
control should be critically assessed.
Desirable recommendations
• Epidemiological research is required to
ascertain the risk factors for and transmission
dynamics of community-based Alert organ-
isms, e.g., community-acquired MRSA.
Surveillance and control policies for antibiotic-
resistant Alert organisms
High-priority recommendations
• International studies should be established to
measure the burden of disease (cost, morbid-
ity, mortality, resource utilisation, hospital bed
occupancy) resulting from healthcare-associ-
ated MRSA and Alert organism infections in
Europe.
• Epidemiological investigations should be con-
ducted across Europe to estimate the duration
of carriage of MRSA ⁄Alert organisms after
hospital discharge, and to determine the size
of the population reservoir of MRSA ⁄Alert
organisms in the extended-care sector and the
community.
• Controlled intervention trials should be per-
formed to confirm ⁄ compare the effectiveness
of active control measures for MRSA ⁄Alert
organisms.
• Health economics studies should be under-
taken to determine the cost-effectiveness and
cost ⁄benefit ratio of applying rapid microbio-
logical methods for screening and detection of
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MRSA ⁄Alert organism carriage in high-risk
patients admitted to healthcare settings such
as intensive care units.
Desirable recommendations
• Intervention trials should be conducted to
determine effective prevention methods
against infection with community-acquired
MRSA.
Establishment of electronic typing databases for key
Alert organisms
High-priority recommendations
• Studies on intra- and inter-laboratory repro-
ducibility and standardisation of typing meth-
ods, including bioinformatics data analysis,
should be performed.
• New and better typing methods, exploiting
new proteomic and genomic approaches,
should be investigated and developed.
• The role and cost-effectiveness of typing in
containing the increase in antibiotic resistance
should be investigated.
• Research should be performed to identify
particular virulent and ⁄ or epidemic clones
for infection control purposes, and to find
out why these particular clones are import-
ant.
• Epidemicity and virulence ⁄pathogenicity
mechanisms should be investigated in import-
ant epidemic clones.
COMMENTARY
For the first time, ARPAC has provided a pan-
European picture, albeit a snapshot, of the
attempts being made to control antimicrobial
resistance. Of course, the ARPAC project did not
attempt to answer all possible questions; indeed,
it probably posed more questions than it
answered. The project study design did not allow
cause and effect to be attributed. Nevertheless,
many fascinating associations were identified,
which both confirmed previous work and pointed
the way to further studies. Serious shortcomings
were also documented in many aspects of Euro-
pean measures for the control of antimicrobial
resistance. These shortcomings are likely to be
underestimated by the project, as the hospitals
that took part in ARPAC are likely to be among
the most active in their attempts to control the
problem, simply because of the self-selecting
nature of a voluntary study.
The recommendations made at the Consensus
Conference are, of necessity, not strictly evidence-
based. They arose from a synthesis of findings
from the ARPAC project and expert opinion, so
ably presented at the Consensus Conference by
many authorities in the field, and discussed
exhaustively by the participants. After the con-
ference, the recommendations were refined by the
ARPAC project Steering Group, before their
presentation in this report.
Several caveats regarding controversial issues
that were discussed at the Conference are worth
mentioning. Although priority is given to specific
control of MRSA infections in many of the
ARPAC recommendations, it was emphasised
that many other emerging or regionally epidemic
resistant Alert organisms may well deserve equal
priority at local, national or regional levels.
Therefore, focus on MRSA should be no reason
for complacency about other epidemiologically
relevant organisms. With regard to surveillance of
Alert organisms, it was agreed that there is no
easy access to ‘quality indicators’ for control
efforts. Whereas calculation of the proportion of
resistant strains in a species (e.g., % MRSA ⁄
S. aureus isolates) is often done for the sake of
routine accessibility from laboratory data, this
practice was recognised as being clearly insuffi-
cient as an indicator of effectiveness for control
measures. Benchmarking of healthcare institu-
tions based on such crude indicators is generally
of limited value. Incidence data are far more
relevant for this purpose, and should, ideally, be
adjusted for colonisation pressure and case-mix as
far as possible. Nevertheless, it should be remem-
bered that risk-factor adjustment may divert
substantial skilled resources from prevention
and education efforts towards extensive data
collection and analysis. A related issue is the
increasing public and political demand for public
reporting of Alert organism surveillance data at
facility level. If required, this should be done with
care, and data must be presented and interpreted
in the context of local ⁄ regional epidemiology.
Those with knowledge of previous European
Consensus Conferences on Antimicrobial Resist-
ance, such as those held in Copenhagen in 1998
and in Rome in 2003 [8,9], will, inevitably, notice
some repetition. However, if a recommendation
is worthwhile and has not been implemented
successfully, it is worth repeating. These recom-
mendations must now be carried forward by all
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stakeholders. In particular, the ESCMID Study
Groups involved in the ARPAC Project are
encouraged to mobilise ARPAC participants to
join their activities and contribute further to the
implementation of advanced professional training
and sharing of best practice, harmonisation and
validation of policies, as well as future research.
ESCMID will support these follow-up efforts.
Dissemination of these recommendations to hos-
pital managers, and advocacy of their urgent
implementation, are of primary importance to
unlock solutions to logistic and personnel deficits
by allocation of appropriate resources. It is hoped
that national health authorities, as well as EU
research and public health programmes, will
cooperate to provide financial, regulatory and
logistic support for implementation and refine-
ment of the strategies outlined in these recom-
mendations.
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